{
    "nct_id": "NCT05254743",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2022-02-24",
    "study_start_date": "2022-07-22",
    "study_completion_date": null,
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: Pirtobrutinib"
            },
            {
                "drug_name": "Drug: Ibrutinib"
            }
        ]
    },
    "long_title": "A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)",
    "last_updated": "2025-11-13",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE3",
    "principal_investigator": "NA",
    "principal_investigator_institution": "Eli Lilly and Company",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 662,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "* Confirmed diagnosis of CLL/SLL requiring therapy per iwCLL 2018 criteria",
        "* Part 1 - Known 17p deletion status (wildtype or deleted). Part 2 - Must have deletion of 17p as determined by FISH testing",
        "* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2",
        "* Adequate organ function",
        "* Platelets greater than or equal to \u2265 50 x 10\u2079/liter (L) or \u226530 x 10\u2079/L in participants with documented bone marrow involvement considered to impair hematopoiesis,",
        "* Hemoglobin \u22658 grams/deciliter (g/dL) or \u22656 g/dL in participants with documented bone marrow involvement considered to impair hematopoiesis",
        "* Absolute neutrophil count \u22650.75 x 10\u2079/L or \u22650.50 \u00d7 10\u2079/L in participants with documented bone marrow involvement considered to impair hematopoiesis",
        "* Kidney function: Estimated creatinine clearance \u226530 milliliters per minute (mL/min)",
        "Exclude - Exclusion Criteria:",
        "Exclude - * Known or suspected Richter's transformation to diffuse large B-cell lymphoma (DLBCL), prolymphocytic leukemia, or Hodgkin's lymphoma at any time preceding enrollment",
        "Exclude - * Known or suspected central nervous system (CNS) involvement",
        "Exclude - * A significant history of renal, neurologic, psychiatric, endocrine, metabolic or immunologic disease",
        "Exclude - * Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia \\[AIHA\\], idiopathic thrombocytopenic purpura \\[ITP\\])",
        "Exclude - * Significant cardiovascular disease including ejection fraction \\< 40% and any grade ongoing atrial fibrillation or atrial flutter",
        "Exclude - * Hepatitis B or hepatitis C testing indicating active/ongoing infection, based on Screening laboratory tests",
        "Exclude - * Active cytomegalovirus (CMV) infection",
        "Exclude - * Active uncontrolled systemic bacterial, viral, or fungal infection",
        "Exclude - * Known human immunodeficiency virus (HIV) infection, regardless of cluster of differentiation 4 (CD4) count",
        "Exclude - * Clinically significant active malabsorption syndrome or other condition likely to affect GI absorption of the oral-administered study treatments",
        "Exclude - * Ongoing inflammatory bowel disease",
        "Exclude - * Previous treatment for CLL/SLL - Part 1: Treatment-na\u00efve and previously treated, except prior exposure to BTK inhibitor (covalent or noncovalent).",
        "Exclude - Part 2: participants must be treatment na\u00efve",
        "Exclude - * Concurrent use of investigational agent or anticancer therapy except hormonal therapy",
        "Exclude - * Participants requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist",
        "Exclude - * Use of \\> 20 mg prednisone daily or equivalent dose of steroid at the time of first dose of study drug",
        "Exclude - * Vaccination with a live vaccine within 28 days prior to randomization",
        "Exclude - * Participants receiving chronic therapy with a strong cytochrome P450 (CYP)3A inhibitor (except posaconazole and voriconazole) which cannot be stopped within 3-5 half lives of the CYP3A inhibitor therapy prior to start of study drug treatment",
        "Exclude - * Participants with known hypersensitivity, including anaphylaxis, to any component or excipient of pirtobrutinib or ibrutinib"
    ],
    "short_title": "A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Loxo Oncology, Inc.",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-na\u00efve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Pirtobrutinib Part 1",
                        "arm_internal_id": 0,
                        "arm_description": "Participants will receive pirtobrutinib orally.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Pirtobrutinib",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Ibrutinib",
                        "arm_internal_id": 1,
                        "arm_description": "Participants will receive ibrutinib orally.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Ibrutinib",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Pirtobrutinib Part 2",
                        "arm_internal_id": 2,
                        "arm_description": "Participants will receive pirtobrutinib orally.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Pirtobrutinib",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "clinical": {
                                    "age_numerical": ">=18",
                                    "disease_status": [
                                        "Refractory"
                                    ],
                                    "oncotree_primary_diagnosis": "Lymphoid Neoplasm"
                                }
                            },
                            {
                                "genomic": {
                                    "hugo_symbol": "TP53",
                                    "variant_category": "Copy Number Variation"
                                }
                            }
                        ]
                    }
                ]
            }
        ]
    }
}